The Leishmune®'s Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis

8Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

The Nucleoside hydrolase of Leishmania donovani (NH36) is the main antigen of Leishmune®, the first licensed prophylactic vaccine against canine visceral leishmaniasis (CVL). Compared to untreated controls, mongrel dogs infected with 7 x 108 Leishmania chagasi amastigotes and treated with the NH36-DNA vaccine developed significant increases in the size and proportions of DTH reactions and NH36-specific CD4+ T cell proportions which recognized the C-terminal moiety of NH36. Increases in IgG2/IgG1 anti-NH36 antibody ratios and in CD8+ T cell counts were directed to the NH36 N-terminal. The immunotherapy treatment reduced the parasite load and loss of weight and increased dog survival time. © 2012.

Cite

CITATION STYLE

APA

Borja-Cabrera, G. P., Santos, F. B., Nico, D., Gravino, A. E., Manna, L., Palatnik, M., & Palatnik-de-Sousa, C. B. (2012). The Leishmune®’s Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis. Procedia in Vaccinology, 6, 64–73. https://doi.org/10.1016/j.provac.2012.04.009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free